TWI884914B - 喋啶酮化合物及其用途 - Google Patents

喋啶酮化合物及其用途 Download PDF

Info

Publication number
TWI884914B
TWI884914B TW108114117A TW108114117A TWI884914B TW I884914 B TWI884914 B TW I884914B TW 108114117 A TW108114117 A TW 108114117A TW 108114117 A TW108114117 A TW 108114117A TW I884914 B TWI884914 B TW I884914B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
ring
Prior art date
Application number
TW108114117A
Other languages
English (en)
Chinese (zh)
Other versions
TW202010744A (zh
Inventor
大衛 J 洛佛
蓋 貝米斯
麥克 波伊德
大衛 丹尼葛
鄧紅波
華倫 道許
顧文鑫
羅素 R 胡佛
麥克 阿瑟 二世 強森
馬克 威廉 雷德波爾
布萊恩 李弗
法蘭西斯 馬泰思
瑪琳那 佩妮
達林 竹本
納桑 D 沃爾
天生 王
磐 李
Original Assignee
美商維泰克斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商維泰克斯製藥公司 filed Critical 美商維泰克斯製藥公司
Publication of TW202010744A publication Critical patent/TW202010744A/zh
Application granted granted Critical
Publication of TWI884914B publication Critical patent/TWI884914B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW108114117A 2018-04-24 2019-04-23 喋啶酮化合物及其用途 TWI884914B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862661744P 2018-04-24 2018-04-24
US62/661,744 2018-04-24

Publications (2)

Publication Number Publication Date
TW202010744A TW202010744A (zh) 2020-03-16
TWI884914B true TWI884914B (zh) 2025-06-01

Family

ID=66655428

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108114117A TWI884914B (zh) 2018-04-24 2019-04-23 喋啶酮化合物及其用途

Country Status (11)

Country Link
US (3) US11059826B2 (cg-RX-API-DMAC7.html)
EP (1) EP3784669B1 (cg-RX-API-DMAC7.html)
JP (2) JP7479293B2 (cg-RX-API-DMAC7.html)
CN (1) CN112218865B (cg-RX-API-DMAC7.html)
AR (1) AR114828A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019257651B2 (cg-RX-API-DMAC7.html)
CA (1) CA3097774A1 (cg-RX-API-DMAC7.html)
ES (1) ES2969982T3 (cg-RX-API-DMAC7.html)
IL (1) IL278122B2 (cg-RX-API-DMAC7.html)
TW (1) TWI884914B (cg-RX-API-DMAC7.html)
WO (1) WO2019209757A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3784669B1 (en) 2018-04-24 2023-10-25 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
US12617784B2 (en) 2019-01-29 2026-05-05 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. AKT inhibitor
AU2020368368B2 (en) * 2019-10-14 2026-03-19 The Regents Of The University Of California Broad spectrum anti-cancer compounds
WO2022023339A1 (en) 2020-07-29 2022-02-03 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
EP4238974A4 (en) * 2020-10-28 2024-10-23 Adlai Nortye Biopharma Co., Ltd. HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND
TW202334157A (zh) * 2022-01-29 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Wnt通路抑制劑化合物
TW202333697A (zh) * 2022-01-30 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 Wnt通路抑制劑化合物
CN114436918B (zh) * 2022-02-23 2023-05-23 郑州大学 环丁-1-烯胺类化合物及其制备方法和在药物中的应用
WO2024022365A1 (zh) * 2022-07-28 2024-02-01 杭州阿诺生物医药科技有限公司 一种Wnt通路抑制剂化合物
US20240217951A1 (en) * 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018182A1 (en) * 2004-08-14 2006-02-23 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060052383A1 (en) * 2004-08-25 2006-03-09 Boehringer Ingelheim International Gmbh New dihydropteridione derivatives, process for their manufacture and their use as medicament

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
UY27427A1 (es) 2001-09-04 2003-03-31 Boehringer Ingelheim Pharma Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
AU2011226830A1 (en) * 2004-08-14 2011-10-13 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
EP2958919B1 (en) 2013-02-21 2019-05-22 Boehringer Ingelheim International GmbH Dihydropteridinones i
JP6072308B2 (ja) 2013-02-21 2017-02-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンii
KR20160111520A (ko) 2014-01-31 2016-09-26 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
WO2015193229A1 (de) 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
CA2986441A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN105801582A (zh) * 2016-04-12 2016-07-27 合肥工业大学 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途
EP3784669B1 (en) * 2018-04-24 2023-10-25 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018182A1 (en) * 2004-08-14 2006-02-23 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060052383A1 (en) * 2004-08-25 2006-03-09 Boehringer Ingelheim International Gmbh New dihydropteridione derivatives, process for their manufacture and their use as medicament

Also Published As

Publication number Publication date
TW202010744A (zh) 2020-03-16
JP7479293B2 (ja) 2024-05-08
EP3784669A1 (en) 2021-03-03
CN112218865B (zh) 2024-03-12
US20230312587A1 (en) 2023-10-05
IL278122B1 (en) 2023-09-01
US12384790B2 (en) 2025-08-12
US11059826B2 (en) 2021-07-13
CN112218865A (zh) 2021-01-12
US20220363685A1 (en) 2022-11-17
IL278122A (en) 2020-11-30
AU2019257651A1 (en) 2020-10-15
WO2019209757A1 (en) 2019-10-31
AR114828A1 (es) 2020-10-21
US11572364B2 (en) 2023-02-07
JP2021522237A (ja) 2021-08-30
EP3784669B1 (en) 2023-10-25
ES2969982T3 (es) 2024-05-23
AU2019257651B2 (en) 2023-05-25
IL278122B2 (en) 2024-01-01
CA3097774A1 (en) 2019-10-31
JP2023116712A (ja) 2023-08-22
US20190322673A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
JP7479293B2 (ja) プテリジノン化合物およびその使用
CN116554168B (zh) Cxcr4抑制剂及其用途
AU2020282759A1 (en) TEAD inhibitors and uses thereof
US11332470B2 (en) CXCR4 inhibitors and uses thereof
KR20230172548A (ko) Mek 억제제 및 이의 용도
TW202108571A (zh) Tead抑制劑及其用途
WO2022120355A1 (en) Tead degraders and uses thereof
EP3846793B1 (en) Eif4e inhibitors and uses thereof
TW202146393A (zh) Eif4e抑制劑及其用途
CA3098335A1 (en) Antiproliferation compounds and uses thereof
JP2025523621A (ja) Usp1阻害剤及びその使用
JP2022538138A (ja) Cxcr4阻害剤およびその使用
HK40050670A (en) Substituted piperidines as cxcr4-inhibitors
EA047483B1 (ru) Ингибиторы tead и их применения
HK40006048B (en) Cxcr4 inhibitors and uses thereof
HK40006048A (en) Cxcr4 inhibitors and uses thereof